CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release.
The authorization includes those 12 and up based on modeling that shows it would have similar effects in children as in adults if they were a certain weight, but Pfizer said in its release that the data from the new trial"will provide further support for the dose recommendations in this population, as well as potentially expand the indication to younger age groups and lower weights."
"There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death," said Dr. Mikael Dolsten, Pfizer's chief scientific officer and president of worldwide research, development and medical, in the release.
So are we still trying to figure out the origin of the virus Why did China shut down travel to & from Wuhan within China but they still allowed flights out of China to other nations Why is the USA paying for 'gain of function' research in China & cruel experiments w/ animals?
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ABC7Chicago - 🏆 284. / 63 Read more »
Source: ABC7Chicago - 🏆 284. / 63 Read more »